ReviewFrontiers in pediatrics2025
Current research status of third-generation sequencing technology in thalassemia detection.
Review in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalassemia is a hereditary hemolytic disorder primarily caused by defects in the hemoglobin genes, which impede the synthesis of hemoglobin peptide chains. This disease is mainly classified into two types: α and β. Currently, there is no effective treatment available that can completely cure this disease. The conventional screening techniques for thalassemia currently used in clinical practice have significant shortcomings, posing risks of missed diagnoses and misdiagnoses. As a molecular detection technology that has emerged in recent years, third-generation sequencing can specifically address the shortcomings of conventional detection methods, enhance the positive detection rate for novel thalassemia variants, and demonstrate broad application prospects. However, it remains in the stage of technical exploration and refinement. This review aims to systematically organize and thoroughly analyze relevant research literature on the application of third-generation sequencing technology in thalassemia detection. It seeks to comprehensively understand the current status of utilization of this technology in thalassemia research, thereby fully leveraging its technical advantages to support the prevention, control, and management of thalassemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.